Zobrazeno 1 - 10
of 98
pro vyhledávání: '"Joan M. Korth-Bradley"'
Autor:
Yongqiang Zhao, Binyu Luo, Lihong Xu, Pablo Rendo, Xuefeng Wang, Runhui Wu, Jeremy Rupon, Jing Sun, Depei Wu, Feifei Sun, Francois Huard, Renchi Yang, Yingxue Cathy Liu, Jie Jin, Chenghao Jin, Joan M. Korth-Bradley
Publikováno v:
Journal of Blood Medicine. 11:439-448
Introduction Moroctocog alfa albumin-free cell culture (AF-CC) increases plasma levels of factor VIII (FVIII) activity and, in China, is indicated for the control and prevention of bleeding episodes in patients with hemophilia A. This study aimed to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98d8878ee448057b9b05fd6b78974dec
https://doi.org/10.2147/jbm.s241605
https://doi.org/10.2147/jbm.s241605
Autor:
Bonnie Vlahos, Pavol Polák, Ingrid Louw, Ron Pedersen, Joan M. Korth-Bradley, Jean‐Claude Becker, Stefanie Gaylord, Theresa Williams, Porin Perić
Publikováno v:
European Journal of Rheumatology, Vol 6, Iss 1, Pp 23-28 (2019)
European Journal of Rheumatology
European Journal of Rheumatology
Objective: To evaluate the immunogenicity, safety, and efficacy of etanercept (ETN) manufactured using the serum-free, high-capacity manufacturing (SFHCM) process in patients with rheumatoid arthritis (RA). ----- Methods: In this global, multicenter,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e94829c7c42e4a7939bd6a4f13e161b6
http://www.eurjrheumatol.org/eng/makale/3185/217/Full-Text
http://www.eurjrheumatol.org/eng/makale/3185/217/Full-Text
Autor:
Pablo Rendo, Kaan Kavakli, Marcus E. Carr, Lynne Smith, Bartholomew J Tortella, Joan M. Korth-Bradley
In a pivotal, multicenter, open-label study, 25 patients aged 12-54 years with moderately severe/severe hemophilia B received on-demand nonacog alfa (6 months; dose at investigator's discretion) followed by once-weekly prophylaxis with nonacog alfa 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae56f98e0083b772a756c01a839becc8
https://hdl.handle.net/11454/77394
https://hdl.handle.net/11454/77394
Autor:
L. Rusen, Jeremy Rupon, Pablo Rendo, Kaan Kavakli, Joanne Fuiman, Joan M. Korth-Bradley, James Baumann, Christine Alvey, Francois Huard, Lynne Smith
Publikováno v:
Haemophilia. 24:604-610
WOS: 000442583600048
PubMed ID: 29582525
IntroductionThe pharmacokinetics (PK), efficacy and safety of moroctocog alfa (AF-CC) have been demonstrated in haemophilia A patients aged 6years. AimThese studies aimed to further describe moroctoc
PubMed ID: 29582525
IntroductionThe pharmacokinetics (PK), efficacy and safety of moroctocog alfa (AF-CC) have been demonstrated in haemophilia A patients aged 6years. AimThese studies aimed to further describe moroctoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d481121f47a0eff06ae5cc64c54cf64
https://doi.org/10.1111/hae.13466
https://doi.org/10.1111/hae.13466
Publikováno v:
Clinical and Translational Science. 11:283-288
An open-label, single-dose, randomized, two-period, crossover study comparing the pharmacokinetics of factor VIII activity in plasma (FVIII:C) after administration of an albumin-free presentation of moroctocog alfa (test) and moroctocog alfa manufact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec7050a0260167a9442b6e94fa6d3dfd
https://doi.org/10.1111/cts.12544
https://doi.org/10.1111/cts.12544
Publikováno v:
Clinical and Translational Science. 11:38-45
A randomized, parallel-dose study assessed the pharmacokinetics (PK) and pharmacodynamics (PD) of etanercept in 61 patients with rheumatoid arthritis (RA) who received doses from 10 mg once-weekly to 50 mg twice-weekly for 4 weeks. Empiric applicatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69c31b69165aa9afd6a0c3ddf625825e
https://doi.org/10.1111/cts.12502
https://doi.org/10.1111/cts.12502
Publikováno v:
Clinical Pharmacology & Therapeutics. 102:977-988
This study investigated the disposition of coagulation factor VIII activity in 754 patients with moderate to severe hemophilia A following the administration of moroctocog alfa, a B-domain deleted recombinant factor VIII. Data analyzed included patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f522fd16d844f9abe985c0a0959ad64
https://doi.org/10.1002/cpt.716
https://doi.org/10.1002/cpt.716
Autor:
Joan M. Korth-Bradley, Steve Riley, Frank E. Shafer, Anna Plotka, David Robert John Readett, Brinda Tammara
Publikováno v:
The Journal of Clinical Pharmacology. 57:1315-1321
Rivipansel is a pan-selectin inhibitor in phase 3 development for the treatment of vaso-occlusive crises in patients with sickle cell disease. This single-dose, randomized, 3-period, 3-treatment (400 mg moxifloxacin open-label, 4 g rivipansel-blinded
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed1175f4227258ba765f938eff06a1f0
https://doi.org/10.1002/jcph.924
https://doi.org/10.1002/jcph.924
Autor:
David Robert John Readett, Anna Plotka, Hua Wei, Kelly A. Ryan, Brinda Tammara, Annie Fang, Joan M. Korth-Bradley, Frank E. Shafer
Publikováno v:
Clinical pharmacology in drug developmentReferences. 9(8)
Two studies evaluated the effects of renal and hepatic impairment on pharmacokinetics and safety of rivipansel (NCT02813798, NCT02871570). A single intravenous 840-mg rivipansel dose was administered to subjects with renal impairment or normal renal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1081ca5f000b278dee583089fbd8e1f
https://pubmed.ncbi.nlm.nih.gov/32579796
https://pubmed.ncbi.nlm.nih.gov/32579796
Autor:
Nathalie Baillon-Plot, M. Anne Hickman, Joan M. Korth-Bradley, Margaret Tawadrous, Mike Sharland, Humberto Díaz-Ponce, Michele Wible, Hal Tucker, Keith A. Rodvold, Susan Raber
Publikováno v:
The Pediatric infectious disease journal. 38(7)
BACKGROUND: The need for antimicrobial therapies effective against multidrug resistant organisms for children remains unmet. Tigecycline shows antibacterial activity across a broad spectrum of bacteria and is approved for treating complicated skin an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11927d5b3861fb121ce004cd362cd999
https://pubmed.ncbi.nlm.nih.gov/31192975
https://pubmed.ncbi.nlm.nih.gov/31192975